Human papillomavirus 16 (HPV16) and HPV52 E6-specific immunity in HIV-infected adults on combination antiretroviral therapy.

MLA

Leng, C. Y., et al. “Human Papillomavirus 16 (HPV16) and HPV52 E6-Specific Immunity in HIV-Infected Adults on Combination Antiretroviral Therapy.” HIV Medicine, vol. 18, no. 5, May 2017, pp. 321–31. EBSCOhost, https://doi.org/10.1111/hiv.12432.

APA

Leng, C. Y., Low, H. C., Chua, L. L., Chong, M. L., Sulaiman, H., Azwa, I., Roberts, J. M., Kamarulzaman, A., Rajasuriar, R., & Woo, Y. L. (2017). Human papillomavirus 16 (HPV16) and HPV52 E6-specific immunity in HIV-infected adults on combination antiretroviral therapy. HIV Medicine, 18(5), 321–331. https://doi.org/10.1111/hiv.12432

Chicago

Leng, C Y, H C Low, L L Chua, M L Chong, H Sulaiman, I Azwa, J M Roberts, A Kamarulzaman, R Rajasuriar, and Y L Woo. 2017. “Human Papillomavirus 16 (HPV16) and HPV52 E6-Specific Immunity in HIV-Infected Adults on Combination Antiretroviral Therapy.” HIV Medicine 18 (5): 321–31. doi:10.1111/hiv.12432.